No abstract

A series of multihydroxyl (2, 4, and 8) terminated poly(ethylene glycol)s and their biodegradable, biocompatible, and branched barbell‐like (PLGA)n‐b‐PEG‐b‐(PLGA)n (n = 1, 2, 4) copolymers have been synthesized. The lengths of the PLGA arms were varied by controlling the molar ratio of monomers to hydroxyl groups of PEG ([LA+GA]0/[OH]0 = 23, 45, 90). Chemical structures of synthesized barbell‐like copolymers were confirmed by both 1H and 13C‐NMR spectroscopies. Molecular weights were determined by 1H‐NMR end‐group analysis and gel permeation chromatography. The result of hydrolytic degradation indicated that the rate of degradation increased with the increase of arm numbers or with the decrease of arm lengths. The thermal properties were evaluated by using differential scanning calorimetry and a thermogravimetric analysis. The results indicated that the thermal properties of barbell‐like copolymers depended on the structural variations. The morphology of (PLGA)n‐PEG‐(PLGA)n copolymers self‐assembly films were investigated by atomic force microscope, the results indicated that the microphase separation existed in (PLGA)n‐PEG‐(PLGA)n copolymers. Because of the favorable biodegradability and biocompatibility of the PLGA and PEG, these results may therefore create new possibilities for these novel structural amphiphilic barbell‐like copolymers as potential biomaterials. © 2008 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 46: 3802–3812, 2008

A novel dual-imaging cisplatin-carrying molecular cargo capable of performing simultaneous optical and MR imaging is reported herein. This long-lasting MRI contrast agent (r1 relaxivity of 23.4 mM-1s-1 at 3T, 25 oC) is a photo-activated cisplatin prodrug (PtGdL) which enables real-time monitoring of anti-cancer efficacy. PtGdL is a model for monitoring the drug delivery and anti-cancer efficacy by MRI with a much longer retention time (24 hours) in several organs such as renal cortex and spleen than GdDOTA and its motif control GdL. Upon complete release of cisplatin, all PtGdL is converted to GdL enabling subsequent MRI analyses of therapy efficacy within its reasonably short clearance time of 4 hours. There is also responsive fluorescence enhancement for monitoring by photon-excitation.

No abstract

No abstract